ABSTRACT

Introduction

Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections share common routes of transmission. HBV/HCV coinfection can lead to interactions affecting mechanisms of infection and therapy.

Areas covered

In the review, we present epidemiology of HBV/HCV coinfection and current therapeutic options for both viruses. The possibility of drug–drug interactions during the treatment of coinfected patients is discussed. However, the major part of the review is dedicated to interactions between viruses and risk of HBV reactivation during HCV treatment with direct-acting antivirals (DAA). Finally, we analyze available international and national guidelines for the management of HBV reactivations related to DAA administration.

Expert opinion

The most important international societies’ guidelines include comments on HBV/HCV coinfection, but due to their inconsistency we present a proposal of management for HBV/HCV coinfected patients focusing mostly on HBV reactivation in patients treated for HCV. We provide some advice that should be considered in future guidelines for the management of HBV/HCV coinfection.

中文翻译：

---

乙型肝炎和丙型肝炎合并感染的管理：专家评论。

摘要

介绍

乙型肝炎病毒（HBV）和丙型肝炎病毒（HCV）感染具有共同的传播途径。HBV / HCV合并感染可导致相互作用，从而影响感染和治疗的机制。

覆盖区域

在这篇综述中，我们介绍了HBV / HCV合并感染的流行病学以及两种病毒的当前治疗选择。讨论了在合并感染患者治疗期间药物相互作用的可能性。但是，本综述的主要内容是研究病毒与病毒之间的相互作用以及用直接作用抗病毒药（DAA）进行HCV治疗期间HBV重新激活的风险。最后，我们分析了与DAA管理相关的HBV激活管理的可用国际和国家指南。

专家意见

国际上最重要的指南包括对HBV / HCV合并感染的评论，但是由于它们的不一致，我们提出了一项针对HBV / HCV合并感染患者的治疗方案，主要侧重于接受HCV治疗的患者中的HBV激活。我们提供一些在HBV / HCV合并感染管理的未来指南中应考虑的建议。